Lucina Biotherapeutics is pioneering a new class of therapeutics designed to restore essential molecules lost with age. Leveraging advanced synthetic biology, we develop lipid-based interventions that address the molecular drivers of age-related diseases. Our lead program targets dry age-related macular degeneration (AMD), a condition driven by the decline of retina-specific lipids. By replenishing these vital lipids, Lucina aims to preserve vision, enhance cellular resilience, and extend human healthspan and longevity.

Lucina Biotherapeutics

Org chart

Teams

Offices

Similar companies